$Calliditas Therapeutics (CALT.US)$ NEWS Calliditas Therapeu...
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon compared to placebo.
Positive quality of life outcomes with no meaningful differences between Nefecon and placebo groups.
Favorable response to Nefecon treatment in Asian and White patient populations with reduced UPCR and delays in kidney function decline events.
Nefecon demonstrated efficacy and tolerability across different racial and ethnic groups.
Safety information highlighted contraindications, warnings, precautions, and potential adverse reactions associated with TARPEYO use.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon compared to placebo.
Positive quality of life outcomes with no meaningful differences between Nefecon and placebo groups.
Favorable response to Nefecon treatment in Asian and White patient populations with reduced UPCR and delays in kidney function decline events.
Nefecon demonstrated efficacy and tolerability across different racial and ethnic groups.
Safety information highlighted contraindications, warnings, precautions, and potential adverse reactions associated with TARPEYO use.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
448Followers
64Following
2841Visitors
Follow